You are here: Industry Insights > Rheumatoid Arthritis

News List

Japan MHLW grants marketing approval pharmaasia
July 18, 2017
Japan Ministry of Health, Labor and Welfare (MHLW) grants marketing approval for Olumiant (baricitinib) for the Treatment of Rheumatoid Arthritis.
Lilly's Olumiant gets the thumbs up in Japan for the treatment of rheumatoid arthritis cphi-online
July 05, 2017
In clinical studies, baricitinib has demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies.
Sanofi and Regeneron announce approval of Kevzara to treat rheumatoid arthritis in the European Unio biospectrumasia
June 30, 2017
Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and blocks pro-inflammatory IL-6 mediated signaling
Biologics before triple therapy not cost effective for rheumatoid arthritis europeanpharmaceuticalreview
May 31, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA).
FDA approves Sanofi and Regeneron’s Kevzara for adult rheumatoid arthritis pharmaceutical-technology
May 27, 2017
Sanofi and Regeneron Pharmaceuticals’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely active rheumatoid arthritis (RA).
Sanofi and Regeneron receive CHMP positive opinion for rheumatoid arthritis treatment europeanpharmaceuticalreview
May 02, 2017
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorisation of Sanofi and Regeneron Pharmaceuticals’ Kevzara (sarilumab).
U.S. FDA Issues Complete Response Letter for Baricitinib lilly
April 17, 2017
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA)...
Assay opens way to autoantibodies treatment for rheumatoid arthritis pharmaceutical-technology
February 28, 2017
A new discovery, conducted by researchers at the NYU Langone Medical Center and the University of Pittsburgh, has pointed towards a potential shift in the way that rheumatoid arthritis (RA) could be treated.
EC approves Eli Lilly’s rheumatoid arthritis drug europeanpharmaceuticalreview
February 17, 2017
The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA)。
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show bari Lilly
February 16, 2017
Eli Lilly and Company and Incyte Corporation announced today additional detailed results from RA-BEAM - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - were published in the New England Journal of

Previous page 1 2 3 4 5 6 Next page